RxDoctor Payments Data

Ryan Cain, PA

Physician Assistant · Corvallis, ORNPI 1780918847

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (49.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 45 manufacturers reported payments, led by Amgen at 43.1% of the total. Reporting peaked in 2024 at $48,185 and has fallen 99.9% since, to $26 in 2025. Among physician assistant clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$54,806in general payments, 2019–2025

Across 303 payments — averaging $180.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$24K
  • Johnson & Johnson$13K
  • Genentech USA, Inc.$9K
  • Regeneron$4K
  • Genentech, Inc.$1K
  • Novartis$504
  • plus $4K from 39 others

What the payments were for

  • Consulting fees$11,41821%
  • Speaking & faculty fees$26,99549%
  • Travel & lodging$9,34017%
  • Food & beverage$6,56512%
  • Education$4881%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,806 in reported general payments places this provider in the 95th percentile of 1,756 physician assistant providers in Oregon.

See all physician assistant providers in Oregon

Medicare billing

Part B allowed, 2024
$12,715
Medicare patients
110
Services billed
140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban11$10,228
Tamoxifen Citrate38$1,513
Anastrozole51$1,393
Fentanyl15$1,126
Anagrelide Hcl12$804
Oxycodone Hcl36$793
Hydroxyurea25$608
Letrozole16$482
Levothyroxine Sodium24$391
Gabapentin31$373
Potassium Chloride13$218
Lidocaine-PrilocaineLidocaine/Prilocaine16$172
Pregabalin12$156
Ondansetron OdtOndansetron11$145
Lidocaine Hcl ViscousLidocaine Hcl11$129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$445$10,22811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,756 physician assistant providers in Oregon.

Other physician assistant in Corvallis

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →